All In Biotech

Drug Trial Radar · NCT06679036

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

An Open, Multicenter Phase Ib/II Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Initial Efficacy of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 21, 2025

Primary completion

Oct 30, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.

Conditions

  • Advanced Unresectable or Metastatic Breast Cancer

Interventions

  • HRS-2189Drug

    HRS-2189

  • FluvustatDrug

    Fluvustat

  • HRS-8080Drug

    HRS-8080

  • HRS-6209Drug

    HRS-6209

  • HRS-1358Drug

    HRS-1358

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEs+SAEsTime frame: From the first drug administration to within 30 days for the last treatment dose.
  2. Dose limited toxicity (DLT)Time frame: Up to 28 days.
  3. Maximum tolerated dose (MTD)Time frame: Up to 28 days.
  4. Recommended Phase II Dose (RP2D)Time frame: Up to 28 days.
  5. ORR (objective response rate) - Stage II (efficacy expansion)Time frame: Every 8 weeks lasting about one year.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.